Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial-Reference-Cited by-同舟云学术

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Published:2019-07 Issue: Volume:133 Page:83-87
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Peters S.,Felip E.,Dafni U.^ORCID,Belka C.,Guckenberger M.^ORCID,Irigoyen A.,Nadal E.^ORCID,Becker A.,Vees H.,Pless M.,Martinez-Marti A.,Tufman A.,Lambrecht M.^ORCID,Andratschke N.^ORCID,Piguet A.C.,Kassapian M.,Roschitzki-Voser H.^ORCID,Rabaglio-Poretti M.,Stahel R.A.^ORCID,Vansteenkiste J.^ORCID,De Ruysscher D.

Funder

ETOP

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated;Demaria;Int. J. Radiat. Oncol. Biol. Phys.,2004

2. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing;Liang;J. Immunol.,2013

3. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial;Shaverdian;Lancet Oncol.,2017

4. Overall Survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N. Engl. J. Med.,2018

5. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer;Cancers;2024-09-11

2. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

3. Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era;Physica Medica;2024-07

4. Risk and safety profile in checkpoint inhibitors on non-small-cell lung cancer: A systematic review;Human Vaccines & Immunotherapeutics;2024-06-27

5. Cardiac irradiation combined with an anti-Programmed cell death protein 1 antibody induces time-dependent myocardial injury by regulating the HMGB1/NF-κB pathway;2024-06-14